OxTalks will soon be transitioning to Oxford Events (full details are available on the Staff Gateway). A two-week publishing freeze is expected to start before the end of Hilary Term to allow all future events to be migrated to the new platform. During this period, you will not be able to submit or edit events on OxTalks. The exact freeze dates will be confirmed on the Staff Gateway and via email to identified OxTalks users.
If you have any questions, please contact halo@digital.ox.ac.uk
Effective cancer immunotherapy requires identifying tumor-associated antigens and engineering T cells to recognize them precisely. I will discuss our recent development of complementary technologies: HLA-Shuttle, which reveals hidden antigens in immune-cold tumors; HLA3DB, a database of peptide conformational features; and TRACeR-I, a protein engineering platform for developing antigen-specific binding modules with programmable HLA restriction. Together, these tools address key bottlenecks in the antigen discovery-to-therapy pipeline
